Diagnostic markers in hepatocellular carcinoma using immunohistochemical techniques
Y Ohene-Abuakwa1, M Pignatelli
1Division of Histopathology, Department of Pathology and Microbiology, University of Bristol, Bristol Royal Infirmary, Bristol, UK.
Methods in Molecular Medicine
|February 23, 2011
Summary
Hepatocellular carcinoma (HCC) is a common cancer with poor prognosis due to late diagnosis. Identifying tissue markers for proliferation and cell loss could predict tumor recurrence and improve outcomes for HCC patients.
Area of Science:
- Hepatology
- Oncology
- Pathology
Background:
- Hepatocellular carcinoma (HCC) is a prevalent malignancy with high mortality.
- Chronic hepatitis B and C infections are primary causes of HCC.
- Late diagnosis and postoperative recurrence contribute to poor HCC prognosis.
Purpose of the Study:
- To identify tissue factors that predict tumor recurrence and prognosis in HCC patients.
- To explore the prognostic value of proliferation markers and cell loss indicators.
Main Methods:
- Analysis of tumor specimens from HCC patients.
- Evaluation of proliferation markers like MIB-1 (Ki-67) and PCNA.
- Assessment of cell loss markers, including necrosis and apoptosis.
Main Results:
- Proliferation rate and markers of cell loss (necrosis, apoptosis) show potential prognostic value.
- MIB-1 (Ki-67) and PCNA are studied as proliferation markers in HCC tumor specimens.
Conclusions:
- Identifying prognostic factors in HCC tissues is crucial for guiding adjuvant therapy.
- Proliferation and cell loss markers may aid in predicting HCC recurrence and patient outcomes.
